1. McKenna H, van der Horst GTJ, Reiss I, Martin D. Clinical chronobiology: a timely consideration in critical care medicine. Critical Care. 2018;22(1):124. DOI: 10.1186/s13054-018-2041-x
2. Panda S. Circadian physiology of metabolism. Science. 2016;354(6315):1008-1015. DOI: 10.1126/science.aah4967
3. Zimmet P, Alberti KGMM, Stern N, Bilu C, El-Osta A, Einat H, Kronfeld-Schor N. The Circadian Syndrome: is the Metabolic Syndrome and much more! Journal of Internal Medicine. 2019;286(2):181-191. DOI: 10.1111/joim.12924
4. Méndez-Hernández R, Escobar C, Buijs RM. Suprachiasmatic Nucleus-Arcuate Nucleus Axis: Interaction Between Time and Metabolism Essential for Health. Obesity (Silver Spring). 2020;28(suppl 1):S10-S17. DOI: 10.1002/oby.22774
5. Stevens RG. Artificial lighting in the industrialized world: circadian disruption and breast cancer. Cancer Causes Control. 2006;17(4):501-507. DOI: 10.1007/s10552-005-9001-x
6. Reiter RJ, Sharma R, Rosales-Corral S, Manucha W, Chuffa LGA, Zuccari DAPC. Melatonin and Pathological Cell Interactions: Mitochondrial Glucose Processing in Cancer Cells. International Journal of Molecular Sciences. 2021;22(22):12494. DOI: 10.3390/ijms222212494
7. Anisimov VN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, Semenchenko AV, Yashin AI. Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice. International Journal of Cancer. 2004;111(4):475-479. DOI: 10.1002/ijc.20298
8. Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, Mancini R, Franceschi C. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuro Enocrinology Letters. 2001;22(6):441-447.
9. Hing-Sing Yu, Reiter RJ. Melatonin Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton: CRC Press; 1992;560.
10. van den Heiligenberg S, Deprés-Brummer P, Barbason H, Claustrat B, Reynes M, Lévi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sciences. 1999;64(26):2523-2534. DOI: 10.1016/s0024-3205(99)00210-6
11. Blask DE, Sauer LA, Dauchy R, Holowachuk EW, Ruhoff MS. New actions of melatonin on tumor metabolism and growth. Biological Signals and Receptors. 1999;8(1-2):49-55. DOI: 10.1159/000014568
12. Talib WH. Melatonin and Cancer Hallmarks. Molecules. 2018;23(3):518. DOI: 10.3390/molecules23030518
13. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Najafi M, Sahebkar A. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of Cellular Physiology. 2019;234(5):5613-5627. DOI: 10.1002/jcp.27391
14. Franco PIR, do Carmo Neto JR, Milhomem AC, Machado JR, Miguel MP. Antitumor effect of melatonin on breast cancer in experimental models: A systematic review. Biochimica Et Biophysica Acta-Reviews on Cancer. 2023;1878(1):188838. DOI: 10.1016/j.bbcan.2022.188838
15. Fathizadeh H, Mirzaei H, Asemi Z. Melatonin: an anti-tumor agent for osteosarcoma. Cancer Cell International. 2019;19:319. DOI: 10.1186/s12935-019-1044-2
16. Shen D, Ju L, Zhou F, Yu M, Ma H, Zhang Y, Liu T, Xiao Y, Wang X, Qian K. The inhibitory effect of melatonin on human prostate cancer. Cell Communication and Signaling. 2021;19(1):34. DOI: 10.1186/s12964-021-00723-0
17. Gurunathan S, Qasim M, Kang MH, Kim JH. Role and Therapeutic Potential of Melatonin in Various Type of Cancers. OncoTargets and Therapy. 2021;14:2019-2052. DOI: 10.2147/OTT.S298512
18. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Melanoma. Lancet. 2018;392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9
19. Jasser SA, Blask DE, Brainard GC. Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes Control. 2006;17(4):515-523. DOI: 10.1007/s10552-005-9013-6
20. Li JC, Xu F. Influences of light-dark shifting on the immune system, tumor growth and life span of rats, mice and fruit flies as well as on the counteraction of melatonin. Biological Signal. 1997;6(2):77-89. DOI: 10.1159/000109112
21. Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-39921. DOI: 10.18632/oncotarget.16379
22. Areshidze DA, Kozlova MA, Mnikhovich MV, Bezuglova TV, Chernikov VP, Gioeva ZV, Borisov AV. Influence of Various Light Regimes on Morphofunctional Condition of Transplantable Melanoma B16. Biomedicines. 2023;11(4):1135. DOI: 10.3390/biomedicines11041135
23. Areshidze DA, Kozlova MA, Chernikov VP, Borisov AV, Mischenko DV. Characteristic of Ultrastructure of Mice B16 Melanoma Cells under the Influence of Different Lighting Regimes. Clocks & Sleep. 2022;4(4):745-760. DOI: 10.3390/clockssleep4040056
24. Piérard GE. Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatology. 2012;2012:828146. DOI: 10.5402/2012/828146
25. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J. Characterization of the serotoninergic system in the C57BL/6 mouse skin. European Journal of Biochemistry. 2003;270(16):3335-3344. DOI: 10.1046/j.1432-1033.2003.03708.x
26. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. The FASEB Journal. 2005;19(2):176-194. DOI: 10.1096/fj.04-2079rev
27. Трещалина Е.М., Жукова О.С., Герасимова Г.К., Андронова Н.Г., Гарин А.М. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К; 2012;642-657.
Treschalina EM, Zhukova OS, Gerasimova GK, Andronova NG, Garin AM. Guidelines forpre-clinical study of antitumor activityof drugs. In: Guidelines for pre-clinicaltrials of drugs. Part one. M.: Grif i K; 2012;642-657. (In Russ.).
28. Burghoff S, Gong X, Viethen C, Jacoby C, Flögel U, Bongardt S, Schorr A, Hippe A, Homey B, Schrader J. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice. BMC Cancer. 2014;14:898. DOI: 10.1186/1471-2407-14-898
29. Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, Gwaltney-Brant S, McCrackin MA, Meyer R, Miller D. AVMA Guidelines for the Euthanasia of Animals; American Veterinary Medical Association: Schaumburg, IL, USA; 2013.
30. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocols in Immunology. 2001;Chapter 20:Unit 20.1. DOI: 10.1002/0471142735.im2001s39
31. Ishikawa M, Koga Y, Hosokawa M, Kobayashi H. Augmentation of B16 melanoma lung colony formation in C57BL/6 mice having marked granulocytosis. International Journal of Cancer. 1986;37(6):919-924.
32. Thakuri PS, Liu C, Luker GD, Tavana H. Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling. Advanced Healthcare Materials. 2018;7(6):e1700980. DOI: 10.1002/adhm.201700980
33. Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda, Cepas V, Gonzalez-Menendez P, Fernadez-Vega S, Quiros-Gonzalez I, Sainz RM, Mayo JC. Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. International Journal of Molecular Sciences. 2020;21(2):548. DOI: 10.3390/ijms21020548
34. Blask DE, Dauchy RT, Sauer LA, Krause JA. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis. 2004;25(6):951-960. DOI: 10.1093/carcin/bgh090
35. Fischer TW, Zmijewski MA, Zbytek B, Sweatman TW, Slominski RM, Wortsman J, Slominski A. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. International Journal of Oncology. 2006;29(3):665-672. DOI: 10.3892/ijo.29.3.665
36. Potez M, Trappetti V, Bouchet A, Fernandez-Palomo C, Güç E, Kilarski WW, Hlushchuk R, Laissue J, Djonov V. Characterization of a B16-F10 melanoma model locally implanted into the ear pinnae of C57BL/6 mice. PLoS One. 2018;13(11):e0206693. DOI: 10.1371/journal.pone.0206693
37. Lazova R, Klump V, Pawelek J. Autophagy in cutaneous malignant melanoma. Journal of Cutaneous Pathology. 2010;37(2):256-268. DOI: 10.1111/j.1600-0560.2009.01359.x
38. Checinska A, Soengas MS. The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell & Melanoma Research. 2011;24(6):1116-1132. DOI: 10.1111/j.1755-148X.2011.00927.x
39. Nakagawa H, Hori Y, Sato S, Fitzpatrick TB, Martuza RL. The nature and origin of the melanin macroglobule. Journal of Investigative Dermatology. 1984;83(2):134-139. DOI: 10.1111/1523-1747.ep12263325
40. Cabrera J, Negrín G, Estévez F, Loro J, Reiter RJ, Quintana J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. Journal of Pineal Research. 2010;49(1):45-54. DOI: 10.1111/j.1600-079X.2010.00765.x
41. García-Navarro A, González-Puga C, Escames G, López LC, López A, López-Cantarero M, Camacho E, Espinosa A, Gallo MA, Acuña-Castroviejo D. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. Journal of Pineal Research. 2007;43(2):195-205. DOI: 10.1111/j.1600-079X.2007.00463.x
42. Paternoster L, Radogna F, Accorsi A, Cristina Albertini M, Gualandi G, Ghibelli L. Melatonin as a modulator of apoptosis in B-lymphoma cells. Annals of the New York Academy of Sciences. 2009;1171:345-349. DOI: 10.1111/j.1749-6632.2009.04910.x
43. Ladányi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell & Melanoma Research. 2015;28(5):490-500. DOI: 10.1111/pcmr.12371
44. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1(8):1323-1343.